Open AccessTrends of Ordering Hypercoagulability Work-Up at an Academic Medical Center
Author(s) -
Marjan Alidoost,
Gabriella A Conte,
Varsha Gupta,
Swapnil Patel,
Ishan Patel,
Mohammed Shariff,
Shreya Gor,
Michael Levitt,
Arif Asif,
Mohammad A. Hossain
Publication year - 2021
Publication title -
journal of blood medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.676
H-Index - 18
ISSN - 1179-2736
DOI - 10.2147/jbm.s271478
Subject(s) - medicine , thrombophilia , medical record , thrombosis , population , retrospective cohort study , incidence (geometry) , malignancy , pediatrics , pulmonary embolism , institutional review board , emergency medicine , intensive care medicine , surgery , physics , environmental health , optics
Venous thromboembolism is a significant clinical event, with an annual incidence of 1-2 per 1000 population. Risk factors include recent surgery, prolonged immobility, oral contraceptive use, and active cancer. Inherited risks include protein C and S deficiencies, antithrombin deficiency, factor V Leiden mutation and prothrombin. These factors can be tested to guide therapy, but current evidence suggests that testing for inherited thrombophilia is not recommended in most inpatient settings. In the era of high value care, hypercoagulable testing for VTE creates a financial burden for the hospital and patients. We performed a retrospective chart review of hypercoagulable orders on VTE patients at our institution.